Marksans Pharma Limited — Board Meeting, 12-08-2025: Outcome of Board Meeting

Marksans Pharma's board has approved the consolidated financial results for the quarter ended June 30, 2025. The company posted a total revenue from operations of Rs 489.35 Cr for the quarter. Net profit for the period came in at Rs 72.96 Cr. These unaudited results received an unmodified opinion from the statutory auditors. Investors should note this update as the company focuses on its core business strategy; no other major operational or strategic announcements were made.